Pharsight Invited To Present On HIV Modeling And Simulation At ASCPT Annual Meeting

Main Category: HIV / AIDS
Also Included In: Conferences
Article Date: 30 Mar 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting at the Orlando World Center Marriott Resort in Orlando, Florida. Dr. Poland will present on April 4, 2008, joining other leading experts from the pharmaceutical industry and academia in a symposium focused on applications of pharmacokinetic/pharmacodynamic (PK/PD) and disease modeling in HIV.

The symposium will provide a forum for scientific discussion and collaborative exchange on model-based approaches to describe and predict drug effects in the treatment of HIV, and will include specific case examples where drug-disease modeling have optimized the clinical development of new anti-HIV drugs. Dr. Poland's presentation, entitled "Using in Vitro and Literature Data to Predict Effects of New Anti-Retrovirals", will describe how PK/PD-viral dynamics models developed using preclinical data and literature data on existing HIV treatments can inform dose-response predictions for new anti-retroviral agents.

In addition to Dr. Poland's presentation, Pharsight scientists have contributed to two separate ASCPT poster presentations that describe model-based approaches to support development decision-making and clinical trial design for drug candidates in oncology and obesity. Further information can be found at http://www.ascpt.org.

"Integrating literature information to permit objective comparisons of drug effects and time course of disease is a critical knowledge management strategy in model-based drug development," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "Model-based approaches continue to show value for enhancing the understanding of complicated diseases in quantitative terms, and for improving the confidence of drug development decisions. Pharsight is pleased to present at this prestigious HIV symposium and to participate at ASCPT, where we look forward to sharing our experience with industry colleagues and interacting with fellow practitioners of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

Pharsight Corporation
http://www.pharsight.com